Tranexamic Acid

Highly effective melasma treatment with a differentiated mechanism: plasmin/PGE2 pathway inhibition upstream of MITF rather than direct tyrosinase suppression. This makes it mechanistically complementary to all tyrosinase inhibitors — and particularly synergistic with niacinamide (which acts at melanosome transfer). 2025 clinical evidence is compelling: RCT (n=50) confirmed oral and topical TXA achieve equivalent MASI reduction (~58.86% vs 50.88%), both superior to baseline; niosomal TXA 2% + niacinamide 4% achieved 66.7% mMASI reduction, outperforming 4% HQ with far fewer adverse reactions. Japan quasi-drug since 2002 (topical) and OTC oral since 2007. Not EU-restricted. Excellent safety profile at cosmetic concentrations. Preferred over hydroquinone by current clinical data. Niosomal delivery is a formulation upgrade worth implementing: same or better efficacy at half the concentration with improved stability. The EU classifies Tranexamic Acid as "permitted". Safety rating: EXCELLENT.

Tranexamic Acid EU regulatory status: permitted. This is based on EU Regulation 1223/2009 and its amendments.

Tranexamic Acid functions as: Plasmin pathway inhibitor; synthetic lysine analogue that inhibits plasminogen/plasmin activation in keratinocytes, reducing UV-induced PGE2 and arachidonic acid release that would otherwise upregulate MITF-driven melanogenesis; brightening via indirect upstream mechanism rather than direct tyrosinase suppression. It is classified as a Active Ingredient in our database. CAS number: 1197-18-8.

adequate The Margin of Safety (MoS) is calculated using SCCS methodology. A MoS above 100 is generally considered safe. Use the MoS Calculator tool to calculate MoS for your specific formulation and product category.